Collectively, the results indicated that this one-shot formulation of miR-125 + Afa/SLN-KL was a breakthrough in simplifying drug preparation and administration and effectively inhibiting tumor progression via the versatile targeting of pan-ErbB- and mTOR-mediated mitochondrial dysfunction and dysregulated metabolism. The gene discussed is EGFR; the disease is neoplasm.